Empfehlungen Nasdaq Semiconductor heute

WR Hambrecht & Co follows up where Merrill Lynch left off yesterday - reiterating bullish sentiment for the chip sector. In their industry update the brokerage firm raises price targets for several high-profile semiconductor companies. Read all about it, and see which companies they are bullish about in today's CNET Investor featured broker story.
Sector: Communications Components
We are reiterating our Strong Buy recommendations for the shares of Altera and Vitesse. We are reiterating our Buy recommendations for the shares of Marvell, Broadcom, and Xilinx. We are raising our 12-month price target for the shares of Broadcom to $60 from $50. We are raising our 12-month price target for the shares of Marvell to $40 from $36. We believe the upcoming Cisco earnings report on August 7 will reinforce our bullish stance on the wireline communications semiconductor sector.
To view the report online, click here:

Peet's Coffee & Tea, Inc.(PEET): Strong Q2:01 Results Drive Profitability; Reiterate Buy
NASDAQ: PEET
Rating: BUY
Sector: Specialty Retail & Branded Consumer
Price Target: $14
Peet's reported impressive Q2:01 results. Peet's posted a profit of $0.01 for Q2:01 vs. ($0.41) a year-ago, beating our estimate of ($0.03). We are fine-tuning our fiscal 2001 estimates. We are taking a more conservative stance and slightly adjusting our revenue estimates for Q3:01 and Q4:01 to reflect the softness in the mail order and Internet segment. We believe PEET shares are attractively valued and trading at a significant discount to its peers. We believe that upside exists to our financial model, which should lead to multiple expansion. The company is well positioned to deliver revenue growth of at least mid-teens annually and drive earnings growth well in excess of 25% per year, in our opinion. We reiterate our Buy rating. iqc.go2net.com/magic/...t=candle&symbol=PEET&lotemp=&s=linear" style="max-width:560px" >


Walgreen Company is principally engaged in the retail drugstore business. As of 12/00, the Co. operated 3,259 retail drugstores and two mail service facilities in 39 states and Puerto Rico. For the 6 months ended 2/01, net sales rose 15% to $12.04B. Net income rose 24% to $455.3M. Revenues reflect sales gains in existing stores and added sales from new stores. Earnings also benefitted from lower headquarter expenses and lower store salaries and expenses. Salomom Smith+ CSFB
Walgreen Company  2 Upgrades
NYSE: WAG
iqc.go2net.com/magic/...rt=candle&symbol=WAG&lotemp=&s=linear" style="max-width:560px" >

Symyx Technologies: Buy (UBS Warburg)

Die Analysten von UBS Warburg bezeichnen die Aktie des amerikanischen
Chemieunternehmens Symyx Technologies als klare Buy-Position.

Symyx Technologies mit Sitz in Santa Clara, Kalifornien, entwickle
unterstützende Instrumente sowie Software für die pharmazeutische und
die chemische Industrie. Am 26. Juli habe das Unternehmen, welches im
NASDAQ gelistet werde, seine Ergebnisse für das zweite Quartal des
laufenden Geschäftsjahres veröffentlicht.

Die Analysten von UBS Warburg seien sehr begeistert über die
Performance der Aktie und bekräftigen ihre Buy-Empfehlung für
Symyx Technologies. Zudem sei das Unternehmen in einem überaus
vielversprechenden und zukunftsträchtigen Markt tätig, so dass
man mit dem Kauf von Symyx- Aktien kein Risiko eingehen würde.

Symyx Technologies (WKN 929256)

iqc.go2net.com/magic/...t=candle&symbol=SMMX&lotemp=&s=linear" style="max-width:560px" >

momentan warten,da überkauft